Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer

Breast Cancer Female Clinical Trial

— EARLY-HEART  

Official title:

Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03297346
• Other study ID #: MEDIRAD EARLY-HEART_1.2
• Status: Completed
• Phase: N/A
• Start date: September 1, 2017
• Est. completion date: May 31, 2021

Study information

• Verified date: November 2023
• Source: Institut de Radioprotection et de Surete Nucleaire
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Breast cancer (BC) radiotherapy leads to coincidental radiation of the heart, resulting in increased risk of a variety of heart diseases. Identifying BC patients with the highest risk of radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention. Little has been done on the relationship between dose distribution to different anatomical cardiac structures during radiotherapy and early cardiovascular changes that may lead to cardiac complications.

In the framework of the European project MEDIRAD, the EARLY-HEART multicenter prospective cohort was launched in August 2017, involving 5 investigating centers from France, Netherlands, Germany, Spain and Portugal. With 250 BC patients prospectively followed for 2 years, the main objective is to identify and validate the most important cardiac imaging (echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging) and circulating biomarkers of radiation-induced cardiovascular changes arising in the first 2 years after BC radiotherapy.

Description:

EARLY-HEART is a multicentre prospective cohort study that will include 250 female primary breast cancer cases aged 40-75 years treated with postoperative radiotherapy (RT) alone after breast-conserving surgery using modern planning-CT based RT technologies and followed for 2 years after RT in one of the 5 participating hospitals. In addition to the standard follow-up, patients will need to give repeated blood samples and will undergo repeated cardiac imaging:

• Functional and anatomical cardiac imaging biomarkers will be based on automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed Tomography Coronary Angiography (CT) and cardiac magnetic resonance imaging (MRI).

• Circulating biomarkers (BLOOD) will be based on a panel of multiple classical or novel blood-based biomarkers.

Imaging and circulating biomarkers measurements will be assessed at baseline before RT (ECHO, CT, MRI, BLOOD); at the end of RT (BLOOD); 6 months after RT (ECHO, MRI, BLOOD) and 24 months after RT (ECHO, CT, MRI, BLOOD).

Changes in functional and anatomical cardiac imaging and circulating biomarkers between unexposed status before RT and exposed status after RT at different time points will be first analysed to evaluate the effects of RT on the heart.

All relevant DICOM-data (including planning-CT scans and the ECHO, MRI and CT) will be centralized to the MEDIRAD-ENACT database managed by University of Groningen for automated segmentation of all cardiac substructures (including coronary arteries) to ensure uniformity of the segmentation procedure between centres. The RT planning CTs will be used to generate dose volume histograms and 3D dose maps of the heart and cardiac substructures in order to correlate the localization of any cardiovascular change with the anatomical dose distribution.

In the presence of a cardiac outcome, a multimetric Normal Tissue Complication Probability (NTCP) individual risk model will be constructed and an integrative clinical-biologic risk score will be developed for individual risk prediction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: May 31, 2021
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Female unilateral breast cancer patients

• Treated with primary breast conserving surgery for stage I-III invasive adenocarcinoma of the breast or ductal carcinoma in situ (DCIS)

• Age between 40-75 years at time of start radiotherapy

• World Health Organisation (WHO) performance status 0-1

• Planned for radiotherapy alone to the breast with or without the lymph node areas

• Radiotherapy based on planning-CT scan using either three dimensional conformal radiation therapy (3D-CRT), Intensity-modulated radiotherapy (IMRT), or Volumetric Arc Therapy (VMAT/RapidArc)

• Written Informed consent

Exclusion Criteria:

• Male breast cancer patients

• Neoadjuvant or adjuvant chemotherapy

• M1 disease (metastatic breast cancer)

• Medical history of coronary artery disease and/or myocardial infarction and/or atrial fibrillation

• Previous thoracic or mediastinal radiation

• Contraindications to injection of iodinated contrast such as allergy or renal failure

• Pregnancy or lactation

• Atrial fibrillation detected during electrocardiogram before radiotherapy

• Abnormal echocardiography before radiotherapy defined as: Left Ventricular Ejection Fraction<50%; longitudinal strain = -16%; longitudinal strain rate <-1%, and/or abnormal wall motion

• Presence of myocardial infarction detected during MRI before radiotherapy

• CT or MRI results before radiotherapy requiring revascularisation

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

Intervention

Other:
• Cardiac imaging and circulating biomarkers
Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)

Locations

Country	Name	City	State
France	IRSN - Clinique Pasteur	Toulouse
Germany	Klinikum rechts der Isar der Technischen Universität München	Munich
Netherlands	Academisch Ziekenhuis Groningen	Groningen
Portugal	Associação para Investigação e Desenvolvimento da Faculdade de Medicina	Lisbon
Spain	Institut Català d'Oncologia	Girona

Sponsors (6)

Lead Sponsor	Collaborator
Institut de Radioprotection et de Surete Nucleaire	Academisch Ziekenhuis Groningen, Hospital de Santa Maria, Portugal, Institut Català d'Oncologia, Technical University of Munich, University of Paris 5 - Rene Descartes

Countries where clinical trial is conducted

France,  Germany,  Netherlands,  Portugal,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with decreased myocardial function assessed by echocardiography	Number of patients with an increased of at least 2.5% in the Global Longitudinal Strain (GLS) between baseline and 2 years after radiotherapy	2 years after radiotherapy (baseline measurements performed before radiotherapy)
Secondary	Changes in myocardial function measurements assessed by echocardiography	Increase of the segmental strain measurements (unit of measures:%)	6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
Secondary	Anatomical changes in coronary arteries assessed by cardiac CT	Increase of the number of coronary segments containing any plaque or increase of the calcium score	2 years after radiotherapy (baseline measurements performed before radiotherapy)
Secondary	Myocardial tissue abnormalities assessed by cardiac MRI	Increase of the native mean myocardial T1 mapping value	6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)
Secondary	Changes in circulating biomarkers measurements	Significant increase or decrease in the following biomarkers: classical biomarkers of cardiac injury (C-reactive protein, Troponin I, Troponin T, B-type natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-Pro BNP), beta2-Microglobulin, Galectin 3); Inflammatory cytokines; biomarkers of endothelial activation and dysfunction; Microparticles; MicroRNAs; circulating DNA methylation	at the end of radiotherapy (through radiotherapy completion, an average of 5 weeks after starting date of radiotherapy), 6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy)